Based on a presentation by Miloš Miljković, MD, PhD, Chief Medical Officer, Cartesian Therapeutics at the January 2026 Cure JM Virtual Summit on JIIM Research & Care.
At Cure JM’s recent Virtual Medical Summit, doctors and researchers received an exclusive preview of a brand-new clinical trial that includes juvenile dermatomyositis. Dr. Miloš Miljković shared early insights about Descartes‑08, an experimental approach to CAR‑T therapy. While the original presentation was technical and aimed at medical professionals, this article explains the key points in a way we hope families can understand.
Cartesian is just beginning its first human trial including JDM for their product called Descartes-08, and it represents a new approach that could change how autoimmune diseases are treated. Knowing how it works and what researchers hope to learn can help families understand emerging treatment options that might someday become available to JDM patients.
How Descartes‑08 Works
Most CAR‑T therapies, often used in treating cancer, change a patient’s T cells using viral DNA. This process can require chemotherapy first, inpatient monitoring, and carries small long-term risks to DNA.
Descartes‑08 works differently. Using mRNA instead of DNA, Cartesian engineers the patient’s own T cells to temporarily make a CAR protein. Because this change only lasts a short time:
- The therapy can be given outside the hospital.
- There is no need for chemotherapy first.
- The therapy can be repeated safely, like taking multiple doses of a medicine.
- There is no risk of long-term genetic changes.
Most CAR‑T therapies target CD19, a protein on the immune system’s B-cells. Descartes‑08 instead targets BCMA (B-cell maturation antigen). BCMA is a protein on immune cells that drive disease in JDM and is found on two key types of cells
- Plasma cells, which make harmful autoantibodies.
- Plasmacytoid dendritic cells (PDCs), which cause inflammation.
Focusing on BCMA means Descartes‑08 can attack disease-causing cells without harming most other healthy B cells.
Early Adult Studies Give Clues for Kids
Although pediatric data are just starting to emerge, adult studies in related diseases like myasthenia gravis and lupus provide helpful context:
- Many patients showed meaningful improvements, with some finding relief of symptoms.
- Side effects were mostly mild, like fevers or chills during the infusion.
- Immune function outside harmful cells was largely preserved, including responses to regular vaccines.
While these results are encouraging, we won’t know how safe or effective the therapy is in children until the JDM trial data are available. This could take a few years.
Key Takeaways for Families
- Descartes‑08 is a new CAR‑T therapy entering its first human trial for immune diseases including juvenile dermatomyositis.
- The therapy uses the patient’s own cells and can be given outpatient, without chemotherapy first.
- BCMA targeting attacks harmful immune cells while leaving healthy B cells alone.
- Early adult studies show promising results, but pediatric outcomes are just starting.
- Treatment involves several weekly infusions, with safety checks guiding dosing.
Looking Ahead
Descartes‑08 represents a new approach to CAR‑T therapy for autoimmune disease. Its temporary mRNA modification, outpatient delivery, and targeted approach to key immune cells may make it safer and more controllable than conventional CAR‑T therapies.
Families can follow updates on the Cure JM website for trial progress, enrollment info, safety reports, and early pediatric data.
For Educational Purposes Only
This article summarizes information from a presentation originally delivered to doctors and researchers at the Cure JM Virtual Summit. It is not medical advice. Descartes‑08 is experimental and not approved for any use. Families should consult their child’s healthcare provider before making treatment decisions.
Learn more HERE
